Abstract
Liposomal doxorubicin and nab-paclitaxel are nanoparticle formulations of traditional cancer chemotherapy drugs which have ample clinical experience both pre- and post-nanoparticle modification. The alterations in pharmacokinetics, pharmacodynamics, efficacy, and toxicity compared with their parent compounds are instructive for future development of nanoparticle-based therapies. In this article we review the current status of these agents, emphasizing the alterations in clinical behavior resulting from the nanoparticle formulation of the parent compound.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arcamone, F. (1981) Doxorubicin: Anticancer Antibiotics. Academic Press, New York.
Singal, P. K. and Iliskovic, N. (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339, 900–905.
Gabizon, A. A. (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19, 424–436.
Northfelt, D. W., Martin, F. J., Working, P., et al. (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 36, 55–63.
Symon, Z., Peyser, A., Tzemach, D., et al. (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86, 72–78.
O‘Brien, M. E., Wigler, N., Inbar, M., et al. (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15, 440–449.
von Moos, R., Thuerlimann, B. J., Aapro, M., et al. (2008) Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44, 781–790.
Suffness, M. (1995) Taxol: Science and Applications. CRC Press, Boca Raton.
Rowinsky, E. K. and Donehower, R. C. (1995) Paclitaxel (taxol). N Engl J Med 332, 1004–1014.
ten Tije, A. J., Verweij, J., Loos, W. J., and Sparreboom, A. (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42, 665–685.
Webster, L., Linsenmeyer, M., Millward, M., Morton, C., Bishop, J., and Woodcock, D. (1993) Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85, 1685–1690.
Straubinger, R. M. (1995) Biopharmaceutics of paclitaxel (taxol): formulation, activity and pharmacokinetics. In Suffness M., eds. Taxol: science and applications. CRC Press, Boca Raton.
Hawkins, M. J., Soon-Shiong, P., and Desai, N. (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60, 876–885.
Ibrahim, N. K., Desai, N., Legha, S., et al. (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8, 1038–1044.
Sparreboom, A., Scripture, C. D., Trieu, V., et al. (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11, 4136–4143.
Desai, N., Trieu, V., Yao, Z., et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12, 1317–1324.
Gardner, E. R., Dahut, W. L., Scripture, C. D., et al. (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14, 4200–4205.
Winer, E. P., Berry, D. A., Woolf, S., et al. (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22, 2061–2068.
Gradishar, W. J., Tjulandin, S., Davidson, N., et al. (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23, 7794–7803.
Hope, at $4,200 a Dose – New York Times. 2008. http://www.nytimes.com/2006/10/01/business/yourmoney/01drug.html?pagewanted=1
Heath, J. R. and Davis, M. E. (2008) Nanotechnology and cancer. Annu Rev Med 59, 251–265.
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., and Langer, R. (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2, 751–760.
Lammers, T., Hennink, W. E., and Storm, G. (2008) Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99, 392–397.
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65, 271–284.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Gaitanis, A., Staal, S. (2010). Liposomal Doxorubicin and nab-Paclitaxel: Nanoparticle Cancer Chemotherapy in Current Clinical Use. In: Grobmyer, S., Moudgil, B. (eds) Cancer Nanotechnology. Methods in Molecular Biology, vol 624. Humana Press. https://doi.org/10.1007/978-1-60761-609-2_26
Download citation
DOI: https://doi.org/10.1007/978-1-60761-609-2_26
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-608-5
Online ISBN: 978-1-60761-609-2
eBook Packages: Springer Protocols